About Renibus Therapeutics
Renibus Therapeutics is a company based in Southlake (United States) founded in 2013 by Jeff Keyser and Alvaro F Guillem.. Renibus Therapeutics has raised $153.52 million across 4 funding rounds from investors including Oxford Finance. Renibus Therapeutics offers products and services including RBT-1 and Veverimer. Renibus Therapeutics operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter Southlake, United States
- Founders Jeff Keyser, Alvaro F Guillem
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Renibus Therapeutics Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$153.52 M (USD)
in 4 rounds
-
Latest Funding Round
$95.91 M (USD), Series B
May 25, 2023
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Renibus Therapeutics
Renibus Therapeutics offers a comprehensive portfolio of products and services, including RBT-1 and Veverimer. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
IV drug to reduce risks after cardiac surgery.
Oral treatment for orphan diseases with unmet needs.
Unlock access to complete
Unlock access to complete
Scientific Team
12 people
Leadership Team
10 people
Operations Team
3 people
Finance and Accounting
2 people
Software Development Team
2 people
Human Resources and Administration
1 people
Corporate Team
1 people
Product Management Team
1 people
Unlock access to complete
Funding Insights of Renibus Therapeutics
Renibus Therapeutics has successfully raised a total of $153.52M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $95.91 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $95.9M
-
First Round
First Round
(16 Feb 2022)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2023 | Amount | Series B - Renibus Therapeutics | Valuation |
investors |
|
| Aug, 2022 | Amount | Debt – Conventional - Renibus Therapeutics | Valuation |
investors |
|
| Jul, 2022 | Amount | Series A - Renibus Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Renibus Therapeutics
Renibus Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Oxford Finance. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm focused on the life sciences sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Renibus Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Renibus Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Renibus Therapeutics Comparisons
Competitors of Renibus Therapeutics
Renibus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Renibus Therapeutics
Frequently Asked Questions about Renibus Therapeutics
When was Renibus Therapeutics founded?
Renibus Therapeutics was founded in 2013 and raised its 1st funding round 9 years after it was founded.
Where is Renibus Therapeutics located?
Renibus Therapeutics is headquartered in Southlake, United States. It is registered at Southlake, Texas, United States.
Who is the current CEO of Renibus Therapeutics?
Alvaro F Guillem is the current CEO of Renibus Therapeutics. They have also founded this company.
Is Renibus Therapeutics a funded company?
Renibus Therapeutics is a funded company, having raised a total of $153.52M across 4 funding rounds to date. The company's 1st funding round was a Series A of $23M, raised on Feb 16, 2022.
What does Renibus Therapeutics do?
Renibus Therapeutics was founded in 2013 and is based in Southlake, United States. Focus is placed on the biotechnology sector, where therapeutics for kidney-related conditions are developed. Key products include RBT-1, aimed at preventing acute kidney injury, RBT-2 for treating chronic kidney disease, RBT-3 addressing iron deficiency anemia, and RBT-9 targeting enveloped viruses. The company is led by co-founders Jeff Keyser and Alvaro F. Guillem, who serves as CEO.
Who are the top competitors of Renibus Therapeutics?
Renibus Therapeutics's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
What products or services does Renibus Therapeutics offer?
Renibus Therapeutics offers RBT-1 and Veverimer.
Who are Renibus Therapeutics's investors?
Renibus Therapeutics has 1 investor. Key investors include Oxford Finance.